Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin.

The resveratrol-induced cardiac protection was studied in Zucker obese rats. Rats were divided into five groups: group 1, lean control; group 2, obese control (OC); group 3, obese rats treated orally with 5 mg kg(-1) day(-1) of resveratrol (OR) for 2 wk; group 4, obese rats received 10% glucose solution ad libitum for 3 wk (OG); and group 5, obese rats received 10% glucose for 3 wk and resveratrol (OGR) during the 2nd and 3rd wk. Body weight, serum glucose, and insulin were measured, and then hearts were isolated and subjected to 30 min of ischemia followed by 120 min of reperfusion. Heart rate, coronary flow, aortic flow, developed pressure, the incidence of reperfusion-induced ventricular fibrillation, and infarct size were measured. Resveratrol reduced body weight and serum glucose in the OR compared with the OC values (414 +/- 10 g and 7.08 +/- 0.41 mmol/l, respectively, to 378 +/- 12 g and 6.11 +/- 0.44 mmol/l), but insulin levels were unchanged. The same results were obtained for the OG vs. OGR group. Resveratrol improved postischemic cardiac function in the presence or absence of glucose intake compared with the resveratrol-free group. The incidence of ventricular fibrillation and infarct size was reduced by 83 and 20% in the OR group, and 67 and 16% in the OGR group, compared with the OC and OG groups, respectively. Resveratrol increased GLUT-4 expression and reduced endothelin expression and cardiac apoptosis in ischemic-reperfused hearts in the presence or absence of glucose intake. Thus the protective effect of resveratrol could be related to its direct effects on the heart.

[1]  M. Bohlooly-y,et al.  Opposing Effects of Adiponectin Receptors 1 and 2 on Energy Metabolism , 2007, Diabetes.

[2]  E. Barrett-Connor,et al.  Endothelin-1 and prevalent coronary heart disease in older men and women (the Rancho Bernardo Study). , 2007, The American journal of cardiology.

[3]  G. Bray,et al.  Epidemiology, trends, and morbidities of obesity and the metabolic syndrome , 2006, Endocrine.

[4]  C. Lewis,et al.  Mortality and cardiac and vascular outcomes in extremely obese women. , 2006, JAMA.

[5]  Kieran Clarke,et al.  A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. , 2006, Physiological genomics.

[6]  V. Roger,et al.  Diabetes in heart failure: prevalence and impact on outcome in the population. , 2006, The American journal of medicine.

[7]  M. Patti,et al.  Family history of diabetes is a major determinant of endothelial function. , 2006, Journal of the American College of Cardiology.

[8]  Á. Tósaki,et al.  Potentiation of a Survival Signal in the Ischemic Heart by Resveratrol through p38 Mitogen-Activated Protein Kinase/Mitogen- and Stress-Activated Protein Kinase 1/cAMP Response Element-Binding Protein Signaling , 2006, Journal of Pharmacology and Experimental Therapeutics.

[9]  C. Camargo,et al.  Comparison of long-term mortality across the spectrum of acute coronary syndromes. , 2006, American heart journal.

[10]  A. Gow,et al.  Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Lefer,et al.  Myocardial infarction and heart failure in the db/db diabetic mouse. , 2006, American journal of physiology. Heart and circulatory physiology.

[12]  N. Maulik,et al.  Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. , 2005, Journal of molecular and cellular cardiology.

[13]  M. Oz,et al.  Effects of resveratrol in storage solution on adhesion molecule expression and nitric oxide synthesis in vein grafts. , 2005, The Annals of thoracic surgery.

[14]  C. Wainwright,et al.  Endothelin and the ischaemic heart. , 2005, Current vascular pharmacology.

[15]  Robin A. J. Smith,et al.  Targeting an antioxidant to mitochondria decreases cardiac ischemia‐reperfusion injury , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  N. Renna,et al.  Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. , 2005, American journal of hypertension.

[17]  G. Radda,et al.  PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. , 2005, American journal of physiology. Heart and circulatory physiology.

[18]  T. Cheng,et al.  Resveratrol inhibits angiotensin II-induced endothelin-1 gene expression and subsequent proliferation in rat aortic smooth muscle cells. , 2005, European journal of pharmacology.

[19]  W. Bao,et al.  Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. , 2005, Diabetes.

[20]  G. Lopaschuk Metabolic Abnormalities in the Diabetic Heart , 2002, Heart Failure Reviews.

[21]  T. Cheng,et al.  Inhibition of Cyclic Strain-Induced Endothelin-1 Gene Expression by Resveratrol , 2003, Hypertension.

[22]  啓明 佐々木 Hypoxia/reoxygenation promotes myocardial angiogenesis via an NFκB-dependent mechanism in a rat model of chronic myocardial infarction , 2003 .

[23]  J. Jespersen,et al.  Review: Diabetes as a procoagulant condition , 2002 .

[24]  S. Verma,et al.  Increased endothelin-1 production in diabetic patients after cardioplegic arrest and reperfusion impairs coronary vascular reactivity: reversal by means of endothelin antagonism. , 2002, The Journal of thoracic and cardiovascular surgery.

[25]  K. Clarke,et al.  Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. , 2002, Diabetes.

[26]  J. Jespersen,et al.  Diabetes as a procoagulant condition , 2002 .

[27]  Xianlin Han,et al.  The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. , 2002, The Journal of clinical investigation.

[28]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[29]  R. Carraway,et al.  Naloxone blocks transferred preconditioning in isolated rabbit hearts. , 2001, Journal of molecular and cellular cardiology.

[30]  E. Arikawa,et al.  Long-term endothelin receptor blockade improves cardiovascular function in diabetes. , 2001, American journal of hypertension.

[31]  R. Tian,et al.  Responses of GLUT4-Deficient Hearts to Ischemia Underscore the Importance of Glycolysis , 2001, Circulation.

[32]  Z. Szilvássy,et al.  Functional and biochemical evidence for capsaicin-induced neural endothelin release in isolated working rat heart. , 2001, European journal of pharmacology.

[33]  N. Maulik,et al.  Hypoxia/reoxygenation promotes myocardial angiogenesis via an NF kappa B-dependent mechanism in a rat model of chronic myocardial infarction. , 2001, Journal of molecular and cellular cardiology.

[34]  L. Frémont,et al.  Response of plasma lipids to dietary cholesterol and wine polyphenols in rats fed polyunsaturated fat diets , 2000, Lipids.

[35]  J. Tooke,et al.  Adverse endothelial function and the insulin resistance syndrome , 2000, Journal of internal medicine.

[36]  J. Vanoverschelde,et al.  Glucose for the heart. , 1999, Circulation.

[37]  D L Rothman,et al.  Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.

[38]  Vishva Dixit,et al.  Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway , 1998, The Journal of Biological Chemistry.

[39]  N. Maulik,et al.  Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. , 1998, The American journal of physiology.

[40]  N. Maulik,et al.  Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. , 1998, American journal of physiology. Heart and circulatory physiology.

[41]  L. Opie,et al.  Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with a residual coronary flow. , 1998, Cardiovascular research.

[42]  R. Bergman,et al.  Central Role of the Adipocyte in Insulin Resistance , 1998, Journal of basic and clinical physiology and pharmacology.

[43]  G. Gross,et al.  Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. , 1997, The American journal of physiology.

[44]  L. Groop The molecular genetics of non‐insulin‐dependent diabetes mellitus , 1997, Journal of internal medicine.

[45]  B. Kahn Glucose Transport: Pivotal Step in Insulin Action , 1996, Diabetes.

[46]  G. Radda,et al.  Is a high glycogen content beneficial or detrimental to the ischemic rat heart? A controversy resolved. , 1996, Circulation research.

[47]  John Calvin Reed,et al.  Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[48]  M. Kasuga,et al.  Inhibition of the translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin. , 1994, The Biochemical journal.

[49]  A. Jaffe,et al.  The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. , 1989, Journal of the American College of Cardiology.

[50]  A. Jaffe,et al.  The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. , 1989, Journal of the American College of Cardiology.

[51]  G. Reaven,et al.  Fructose-induced insulin resistance and hypertension in rats. , 1987, Hypertension.